Wyeth

Janssen Alzheimer Immunotherapy

Abbvie Inc.

Abbott Gmbh & Co Kg

Angela Kantor

Nicholas W Warne

Geertruida Machteld Veldman

Boris Labkovsky

Jochen G Salfeld

Zehra Kaymakcalan

Michael White

Michael Roguska

Paul Sakorafas

Subhashis Banerjee

Angela Widom

Thor Las Holtet

Elaine Joy Derbyshire

Daniel Edward Tracey

Sara Carmen

John Gawain Elvin

Alexander Robert Duncan

Michael Paskind

Stephen Smith

Sarah Leila Du Fou

Stuart Friedrich

Amy Venturini

Donna L Luisi

Li Li

Shannon B MacMillan

Erin Soley

Edie Anna Neidhardt

Donna Luisi

Formulations are described that are suitable for storage of proteins, such as antibodies, over a relatively broad range of protein concentrations, pH, and buffer types. Also described are methods of storing a protein and methods of identifying a suitable formulation for storage of a specific protein. In general, a formulation contains low to no surfactant, no to relatively low salt concentrations, and requires a relatively low buffer concentration.

Stabilizing formulations

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Methods of treatment using human antibodies that bind IL-12

The present invention provides formulations for maintaining the stability of A&#x3b2; binding polypeptides, for example, A&#x3b2; antibodies. Exemplary formulations include a tonicity agent such as mannitol and a buffering agent or amino acid such as histidine. Other exemplary formulations include an antioxidant in a sufficient amount as to inhibit by-product formation, for example, the formation of high molecular weight polypeptide aggregates, low molecular weight polypeptide degradation fragments, and mixtures thereof. The formulations of the invention optionally comprise a tonicity agent, such as mannitol, and a buffering agent or amino acid such as histidine. The formulations are suitable for several different routes of administration.

Anti A beta antibody formulation

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Methods for inhibiting the activity of the P40 subunit of human IL-12

Anti A&#x3b2; antibody formulation

Growing community of inventors

Pepperell, MA, United States of America

Angela Kantor